🚀 Gate Square Creator Certification Incentive Program Is Live! 
Join Gate Square and share over $10,000 in monthly creator rewards! 
Whether you’re an active Gate Square creator or an established voice on another platform, consistent quality content can earn you token rewards, exclusive Gate merch, and massive traffic exposure! 
✅ Eligibility: 
You can apply if you meet any of the following: 
1️⃣ Verified creator on another platform 
2️⃣ At least 1,000 followers on a single platform (no combined total) 
3️⃣ Gate Square certified creator meeting follower and engagement criteria 
Click to apply now 👉 
Two late-stage studies of Merck's HIV therapy have met primary goals
On December 19th, Jinshi Data reported that Merck announced on Thursday that its experimental combination therapy for some adult HIV-1 patients has achieved the primary efficacy and safety goals in two late-stage studies. The company stated that its Doravirine/Islatravir combination therapy is not inferior to Gilead Sciences’ triple combination tablet Biktarvy and other various antiretroviral therapies in terms of viral replication inhibition. Merck plans to submit the data to regulatory authorities and present detailed research results at future medical conferences.